Journal
Journal for ImmunoTherapy of Cancer
Publication Date
10-1-2023
Volume
11
Issue
10
First Page
e007725
Document Type
Open Access Publication
DOI
10.1136/jitc-2023-007725
Rights and Permissions
Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson JA. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. J Immunother Cancer. 2023 Oct;11(10):e007725. doi: 10.1136/jitc-2023-007725. © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Leidner, Rom; Conlon, Kevin; McNeel, Douglas G; Wang-Gillam, Andrea; Gupta, Sumati; Wesolowski, Robert; Chaudhari, Monica; Hassounah, Nadia; Lee, Jong Bong; Ho Lee, Lang; O'Keeffe, Jessica A; Lewis, Nancy; Pavlakis, George N; and Thompson, John A, "First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors." Journal for ImmunoTherapy of Cancer. 11, 10. e007725 (2023).
https://digitalcommons.wustl.edu/oa_4/2707
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
